Skip to main content
. 2024 Apr 16;67(7):1192–1205. doi: 10.1007/s00125-024-06146-z

Fig. 2.

Fig. 2

Special considerations for the management of diabetes with glucose-lowering medications in vulnerable subgroups of people with diabetes and CKD, ASCVD, atrial fibrillation or heart failure. DPP-4i, dipeptidyl peptidase 4 inhibitors; SGLT2i, sodium–glucose cotransporter 2 inhibitors. Based on results and approximated estimates in [8595]. This figure is available as part of a downloadable slideset